Exo

Exo is a medical imaging software and devices company that delivers ultrasound technology at the point of care. Exo's handheld device, “Iris,” was launched in September 2023 at USD 3,500 annually. The device combines imaging capabilities with real-time AI guidance leveraging patented pMUT-based technology, enabling caregivers to scan all major organs and guide procedures with ease. As of April 2024, Exo received FDA clearances for its AI tools for analyzing ultrasound images of the heart, lung, bladder, hip, and thyroid, with plans to double the number of clearances by 2025. 

In addition to the handheld device, Exo offers Exo Works, a point-of-care ultrasound workflow solution that streamlines documentation, review, billing, and quality assurance processes. 

In July 2022, Exo acquired Medo to enhance its AI capabilities and leverage Medo's expertise in automated image acquisition and interpretation. 

Key customers and partnerships

Exo's ultrasound technology serves a diverse range of customers in the healthcare sector, including hospitals, clinics, and emergency medical services. In June 2023, Exo partnered with Sana Kliniken AG to expand Exo’s ultrasound platform to Germany. In June 2022, the company partnered with Henry Ford Health to provide caregivers access to its ultrasound technology.

Exo’s notable customers include Geisinger and Wellstart MCG Health.